ライフサイエンスコーパス: preclinical test

1 tection cost, making it easily adaptable for preclinical tests.

2 perties of CIMVs-MSCs in vivo using standard preclinical tests.

3 in vitro approaches may facilitate improved preclinical testing.

4 promulgation of new standards for a rigorous preclinical testing.

5 d by NIH contracts issued in 2004 are now in preclinical testing.

6 ges, each system plays a significant role in preclinical testing.

7 erefore representing a candidate for further preclinical testing.

8 ation-competent adenoviruses are in advanced preclinical testing.

9 d clinical trials since 1998 and more are in preclinical testing.

10 elopment of lesion-specific therapeutics and preclinical testing.

11 nonhuman-primate organ transplant model for preclinical testing.

12 to identify a promising compound for further preclinical testing.

13 dering the ZSF1 obese rat model suitable for preclinical testing.

14 d 25 agents with laboratories to assist with preclinical testing.

15 s, leading us to prioritize this therapy for preclinical testing.

16 of these responses throughout all stages of preclinical testing.

17 r drugs, and are thus difficult to employ in preclinical testing.

18 a power of 80%, providing valid readouts for preclinical testing.

19 , and multiple small-animal models exist for preclinical testing.

20 r studying the pathobiology of ADPKD and for preclinical testing.

21 clinical evaluation: design, production and preclinical testing.

22 res advanced imaging, precluding large-scale preclinical testing.

23 escribe a possible standardized protocol for preclinical testing.

24 ctivity with rodent TfR1 limits conventional preclinical testing.

25 face unique challenges and require reliable preclinical testing.

26 man skull porcine model was designed for the preclinical testing.

27 ools available to researchers for systematic preclinical testing.

28 reases in insulin and GLP-1 secretion during preclinical testing.

29 ment with a number of compounds currently in preclinical testing.

30 or mimicking human ADPKD and can be used for preclinical testing.

31 volunteers, which had not been predicted by preclinical testing.

32 ncer subtypes is critical to enable reliable preclinical testing.

33 decrease the likelihood of hepatotoxicity in preclinical testing.

34 y heart formation or may find application in preclinical testing.

35 uman immunodeficiency virus (HIV) vaccine in preclinical testing.

36 with CRLF2-rearranged ALL and merit further preclinical testing.

37 xenograft models of human retinoblastoma for preclinical testing.

38 d before they can be recommended for further preclinical testing.

39 In preclinical testing, 2-hydroxypropyl-beta-cyclodextrins

40 ne antigens were derived and warrant further preclinical testing against clinically relevant C. diffi

41 design appropriate models and therapies for preclinical testing and clinical trials.

42 nimal model of GBM strongly supports further preclinical testing and downstream process development o

43 y promising new cancer drugs proceed through preclinical testing and early-phase trials only to fail

44 n clinical trials has been due to inadequate preclinical testing and flawed clinical development prog

45 unners of antagonists that proceeded through preclinical testing and into large patient trials to tre

46 ith MCB should be useful for drug discovery, preclinical testing and mechanistic investigation of hum

47 melanoma models that may improve accuracy of preclinical testing and predict efficacy in clinical tri

48 lso highlight the importance of standardized preclinical testing and publicly available data to enabl

49 herapy with CLL-1 CAR T cells (CLL1CART) for preclinical testing and report in vitro and in vivo anti

50 ncer models represent valuable tools for the preclinical testing and translation of different therape

51 t at the stages of candidate identification, preclinical testing, and clinical trials.

52 rther study of hepatic tumorigenesis and for preclinical testing, and identify a subset of human hepa

53 s resulting from ongoing clinical trials and preclinical testing, and manufacturing and/or stability

54 in should greatly facilitate the generation, preclinical testing, and manufacturing of attenuated hMP

55 tor cells in differentiation, tumorigenesis, preclinical testing, and the development of drug resista

56 icacy of antivenoms against dermonecrosis, a preclinical testing approach involves in vivo mouse mode

57 Despite a solid rationale and encouraging preclinical testing, aquaretics have not improved clinic

58 none derivative that is undergoing extensive preclinical testing as a potential anticancer drug.

59 major target of ELP-004, a drug currently in preclinical testing as a therapeutic for inflammatory ar

60 efficacy of CIMVs and supports their further preclinical testing as an effective therapeutic delivery

61 Preclinical testing by drug developers typically involve

62 oxygenated co-cultures stabilizes overnight, preclinical testing can be carried out days or even week

63 -Concept Platform and the US-based Pediatric Preclinical Testing Consortium are being developed to tr

64 As predicted in preclinical testing, daily oral LY353381.HCl is safe, is

65 lthough the mouse is an attractive model for preclinical testing, due to its well-defined immune syst

66 hese failures is that, in most cases, during preclinical testing, efficacy was evaluated on histology

67 Most drugs that pass preclinical tests fail in these patients, emphasizing th

68 ctical, readily standardized live-animal and preclinical test for ovine scrapie.

69 otypes in the shaker1 RPE represents a valid preclinical test for potential therapeutic treatments.

70 nically relevant, cost-efficient approach in preclinical testing for cancer and non-cancer disease ph

71 Several promising drugs are in preclinical testing for FXS; however, bench-to-bedside p

72 is commentary, we discuss recent advances in preclinical testing for pediatric cancer and provide rec

73 and are already in clinical trials, without preclinical testing for safety and efficacy.

74 l as in the design of better high-throughput preclinical tests for assessing the proarrhythmic effect

75 is a promising addition to the repertoire of preclinical tests for drug-induced repolarization abnorm

76 of naturally occurring cancers in dogs as a preclinical testing ground for telomerase targeted thera

77 Preclinical testing has shown that, in comparison with r

78 and mouse HD homolog (HDh) mRNAs to initiate preclinical testing in a knockin mouse model of HD.

79 or DYT1 dystonia and establish the basis for preclinical testing in animal models of the disease.

80 Two challenges exist for preclinical testing in ATRT.

81 accelerate drug development by streamlining preclinical testing in laboratory animals.

82 with FcgammaR contributed to the failure of preclinical testing in macaques to predict toxicity in h

83 patient, which was subsequently validated by preclinical testing in patient-derived xenograft models.

84 Finally, preclinical testing in vivo in xenograft mouse models co

85 Preclinical tests in animal models are key steps in earl

86 Preclinical tests in monkeys defined sites of vaccine vi

87 atment for this deadly disease, we conducted preclinical tests in ovarian tumor-bearing mice to evalu

88 d cost, time of therapeutic development, and preclinical testing, in addition to known pharmacokineti

89 ns of advisory bodies; antigen discovery and preclinical testing, including live vector systems expre

90 IGF1R/IR kinase inhibitor that is undergoing preclinical testing, inhibited constitutive receptor pho

91 uvant clinical trials are rarely preceded by preclinical testing involving neoadjuvant treatment, sur

92 cers in cell culture and in mouse models for preclinical testing is a challenge that has not yet been

93 Failure to predict hepatotoxic drugs in preclinical testing makes it imperative to develop bette

94 thods, our OASIS can serve as an animal-free preclinical test model (newly termed "nonclinical test")

95 Preclinical testing of a mixed chimerism mediated organ

96 ion of peroxisome injury in MS together with preclinical testing of a rational therapy for MS.

97 the possibility of a small-animal model for preclinical testing of an HIV-1 vaccine.

98 Here we report the design and preclinical testing of an inhalable virus-like-particle

99 ure over the short-term, they facilitate the preclinical testing of anti-cancer agents targeting the

100 oint in systemic models of RA as well as for preclinical testing of antiinflammatory therapies.

101 rring malignancies such as osteosarcoma, for preclinical testing of antineoplastic agents offers sign

102 studies and assayed their applicability for preclinical testing of antiviral compounds.

103 Finally, preclinical testing of AZD1208 in a mouse model of ATL r

104 health and disease and to achieve predictive preclinical testing of both prevention measures and pote

105 kidney organoid model offers a platform for preclinical testing of cancer immunotherapies and invest

106 Preclinical testing of candidate microbicides for the pr

107 derived cardiomyocytes is a new paradigm for preclinical testing of candidate therapeutics.

108 Preclinical testing of chemical and physical modulation

109 this gap, we report here the development and preclinical testing of chemically simplified TLR4 agonis

110 In vitro preclinical testing of chimeric antigen receptor (CAR) T

111 Our studies provided a framework for rapid preclinical testing of compounds with antimetastatic act

112 olavirus is currently available, progress in preclinical testing of countermeasures has been made.

113 ine skin is the most commonly used model for preclinical testing of dermal formulations.

114 s of DENV infection and pathogenesis and for preclinical testing of drug and vaccine candidates.

115 ighlight the utility of drug repurposing and preclinical testing of drug combinations for discovering

116 ing through microphysiological platforms for preclinical testing of drugs and modeling of disease tha

117 investigating tuberculosis pathogenesis and preclinical testing of drugs and vaccines.

118 le myeloma may provide new opportunities for preclinical testing of drugs for treatment of the human

119 The development of therapies for HD requires preclinical testing of drugs in animal models that repro

120 int to a new paradigm for identification and preclinical testing of future ALS therapeutics.

121 ector system that should allow comprehensive preclinical testing of HIV-1-based therapeutic vectors i

122 Preclinical testing of human therapeutic monoclonal anti

123 dicate that the rabbit is a useful model for preclinical testing of intranasal meningococcal NOMV vac

124 The in vivo preclinical testing of investigational therapies for mul

125 Our data pave the way to the preclinical testing of listeria-based immunotherapeutic

126 for studying ovarian cancer biology and for preclinical testing of molecularly targeted therapeutics

127 Preclinical testing of MUC1 vaccines revealed existence

128 pathobiology has led to the introduction and preclinical testing of multiple highly specific antifibr

129 This rat model could facilitate preclinical testing of neuroregenerative therapies for p

130 Although increasing used in the preclinical testing of new anti-fibrotic drugs, a thorou

131 r analysis of the pathophysiology of CHD and preclinical testing of new approaches for the prevention

132 Development and preclinical testing of new cancer therapies is limited b

133 Despite this, it is generally ignored in the preclinical testing of new drug candidates.

134 The model will be useful for preclinical testing of new methods of long-term corneal

135 s somatic mouse model may also be useful for preclinical testing of new prophylactic and therapeutic

136 ease in murine modeling of CG, and promising preclinical testing of new therapeutic strategies sugges

137 hat can be used in future studies, including preclinical testing of new therapies or prevention strat

138 odulators and provide a crucial platform for preclinical testing of new therapies.

139 apeutically and have provided a platform for preclinical testing of novel candidate therapies.

140 racterized here offers a powerful system for preclinical testing of novel drugs and drug combinations

141 in patient tumors ex vivo, thereby enabling preclinical testing of novel drugs and helping stratify

142 humanized mouse model may thus be useful for preclinical testing of novel human NK cell-targeted and

143 cally meaningful but underutilized model for preclinical testing of novel strategies for aggressive h

144 This method should afford the means for preclinical testing of novel therapeutic approaches to t

145 ble tools for functional genomic studies and preclinical testing of novel therapeutic approaches.

146 n of malignant mesothelioma pathogenesis and preclinical testing of novel therapeutic modalities.

147 Equids provide a unique opportunity for preclinical testing of novel therapeutics for CHB and to

148 Preclinical testing of novel therapeutics for chronic he

149 normal and malignant B-cell biology and for preclinical testing of novel therapeutics.

150 es guidelines for the design, production and preclinical testing of OVs, emphasizing considerations s

151 ning to accelerate the pace of discovery and preclinical testing of p53 in animal models.

152 Here, we report the development and preclinical testing of patches of transdermal core-shell

153 Furthermore, these animals may be useful for preclinical testing of potential genetic and/or pharmaco

154 etter understand its pathophysiology and for preclinical testing of potential therapeutic agents.

155 ia and industry for more clinically relevant preclinical testing of potential therapeutic targets and

156 -source option for the rapid manufacture and preclinical testing of primary human immune cell therapi

157 vivo MRI to detect it, with implications for preclinical testing of pro-remyelinating agents.

158 d the establishment of a system for rigorous preclinical testing of promising cardioprotective agents

159 Our findings support the preclinical testing of PTP1B inhibitors for prostate can

160 n this article, we will summarize results on preclinical testing of selective and nonselective single

161 Preclinical testing of seroconversion panels showed that

162 w recent progress in the rational design and preclinical testing of small molecules that induce selec

163 ifferent molecular subtypes impedes adequate preclinical testing of stratified therapeutic concepts.

164 uggesting that this is a useful approach for preclinical testing of such agents.

165 nation during disease progression and enable preclinical testing of targeted antimigration therapies.

166 in solid tumor biology and set the stage for preclinical testing of targeted therapeutic approaches.

167 e of human tumors and thus may be useful for preclinical testing of targeted therapy for patients wit

168 describe the discovery and preclinical testing of the first-in-class CDK4-selective

169 cell lineages undergoing transformation and preclinical testing of therapeutic agents targeting a va

170 e the molecular pathogenesis of AITL and for preclinical testing of therapies aimed at targeting dysr

171 e models are rationale candidates for use in preclinical testing of therapies focused on these biolog

172 Currently, preclinical testing of therapies for hepatoblastoma (HB)

173 e, hemoglobinopathies, and malaria, and also preclinical testing of therapies.

174 These promising results suggest further preclinical testing of these complexes for future applic

175 Preclinical testing of these technologies in murine mode

176 Preclinical testing of these vectors has thus far been l

177 o date and provides relevant information for preclinical testing of vaccine candidates and therapeuti

178 del can potentially be developed further for preclinical testing of vaccine candidates.

179 ese challenge stocks should prove useful for preclinical testing of vaccines and other interventions

180 Thus, this humanized mouse model permits preclinical testing of vaccines designed to induce cellu

181 ow a new approach to the rational design and preclinical testing of vaccines that cannot be tested in

182 cation of target and off-target effects, and preclinical testing on relevant cell types for the patho

183 ation and validation and culminated with the preclinical tests on animal disease models.

184 models of AGRIN-related CMS that would allow preclinical testing or studies of postnatal disease prog

185 In preclinical testing, oral gefitinib inhibited the growth

186 In preclinical testing over a decade, the authors developed

187 iotic cell lines and chimeric mouse model as preclinical testing platform, our results, to our knowle

188 complex immune-organoid cultures to provide preclinical testing platforms for precision cancer immun

189 anded dependence receptors are in late-stage preclinical tests, poised for clinical evaluation.

190 nalyzed 67 agents evaluated by the Pediatric Preclinical Testing Program to determine whether a singl

191 ity in several tumor models in the Pediatric Preclinical Testing Program.

192 Current preclinical testing regimes for the detection of human D

193 Tuberculosis (TB) preclinical testing relies on in vivo models including t

194 Importantly, PCAT curates preclinical testing results for 68 models and 79 therape

195 In preclinical testing, SGN-CD33A is more potent than GO ag

196 uman clinical studies require production and preclinical testing that are the same as vaccines enteri

197 ut also describe a valuable animal model for preclinical testing that is coupled with a primary cell-

198 or breast and lymph node imaging, leading to preclinical testing that will produce results that bette

199 CNS indications is hampered by a paucity of preclinical tests that accurately predict drug efficacy

200 Following inconspicuous preclinical testing, the superagonistic anti-CD28 mAb TG

201 tion of product-specific characteristics and preclinical testing to determine whether there is suffic

202 eventually underwent small- and large-animal preclinical testing to ensure safe clinical translation

203 presenting a novel experimental paradigm for preclinical testing to help bridge the gap between nonhu

204 c heart failure, we aimed to start the first preclinical testing to introduce 4F gene therapy as a ca

205 scaffold components, represented sufficient preclinical testing to proceed to a pilot phase I/II cli

206 practice is hindered by the lack of thorough preclinical testing using representative animal models a

207 Preclinical testing was performed of an optical breast l

208 ethod of fixed drug-dose-duration regimen in preclinical testing which will not be feasible in such s

209 Preclinical testing with a positive control, tolvaptan,

210 w compares commonly used animal paradigms of preclinical testing with evolving techniques of induced